No title
Background. In the European Study for Pediatric Ph+ ALL (EsPhALL), a total of 128 patients aged 1 to 18 years diagnosed with ALL and evidence of t(9;22)(q34;q11) received post-Induction Imatinib on top of BFM high risk chemotherapy backbone, either in Good Risk (GR) (after randomization, n=58) or in Poor Risk (PR) (n=70), as defined according to early response to the National induction treatment.
